Upar pet/ct for prognostication and response assessment in patients with metastatic castration-resistant prostate cancer undergoing radium-223 therapy: A prospective phase ii study

Category Primary study
JournalDiagnostics
Year 2021
This article has no abstract
Epistemonikos ID: 4220df92a64e6ef17a8ef141affe2680c1077d5c
First added on: Feb 13, 2025